| 2 min read
Register for free to listen to this article
Listen with Speechify
0:00
2:00
SANTA CLARA, Calif.—Taking a rather large stride inits strategic goals for the clinical diagnostics market, Agilent TechnologiesInc. on May 17 announced the execution of a definitive agreement to acquireGlostrup, Denmark-based Dako, a cancer diagnostic company, for $2.2 billion ona debt-free basis.
 
 
Agilent maintains that Dako will strategicallycomplement Agilent's research technologies and will accelerate growth inrapidly expanding segments of diagnostic markets—and calls it the "next step inAgilent's growing role in clinical diagnostics." And a big step it is, with theall-cash transaction being the largest in Agilent's history.
 
 
"Agilent's strategy in acquiring Dako is aboutstrengthening the company's presence in life science and about revenue growth,"said Agilent President and CEO Bill Sullivan in a news release, characterizingDako as one of the world's leading providers of cancer diagnostics tools. "Dakoemploys extremely talented people with specialized expertise that we highlyvalue. Their knowledge and experience will be very important as we move forwardtogether. In the rapidly growing diagnostics market, Dako's products andcapabilities are a strategic complement to Agilent's existing offerings."
 
Sullivan predicts that together, the combinedcompanies will be able to develop a wider range of products to aid in the fightagainst cancer.
 
 
"Like Agilent, Dako has a long history as a leaderin scientific advancement and a culture that values discovery and innovation,said Lars Holmkvist, CEO of Dako, as he looked at complementary strengthspossessed by the two companies. "We believe that Agilent and Dako are a winningcombination."
 
 
"This deal appears to make sense as Dako isconsidered an attractive asset in tissue diagnostics, a market with robustunderlying fundamentals," wrote Doug Schenkel, an analyst at Cowen & Co.,shortly after the announcement of the deal, adding that Agilent has some $3.9billion in cash outside the United States and that money could be used for morelife-science and diagnostic deals in other countries to avoid U.S. taxes.
 
 
The acquisition is expected to close within thenext 60 days, subject to the satisfaction of customary closing conditions, andAgilent expects the acquisition to be immediately accretive to corporateearnings on a non-GAAP basis.
 
 
Dako provides antibodies, reagents, scientificinstruments and software primarily to customers in pathology laboratories "toraise the standards for fast and accurate diagnostic answers for cancerpatients," according to the companies. Dako also collaborates with a number ofmajor pharmaceutical companies to develop new potential pharmacodiagnostics, orcompanion diagnostics, which may be used to identify patients most likely tobenefit from a specific targeted therapy. Dako's products are sold in more than100 countries employing more than 1,000 people, and in 2010 its annual revenuewas approximately $340 million.
 
 
Looking forward, Agilent said in a conference callabout the acquisition that it expects Dako to generate sales $373 million infiscal year 2013 and noted that it will probably report Dako sales as aseparate segment. If Agilent's predictions of immediate gains from theacquisition hold true, it could be a good boost for the company, given that thelife-science part of Agilent was responsible for roughly one-third of thecompany's 2011 revenue of $5.58 billion.
 
  
 

About the Author

Related Topics

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

GreenCooling

Thermo Scientific™ Centrifuges with GreenCool Technology

Next-generation natural refrigerant cooling system for centrifuges, offering a lower Global Warming Potential and reduced energy consumption.
Clear sample tubes are shown in a clear tote with red lids in a sample prep robot with a blue and silver industrial lab background.

The crucial role of sample preparation in biotherapy manufacturing

Discover how better sample preparation can unlock improved assay accuracy and analytical results.
A black mosquito is shown on pink human skin against a blurred green backdrop.

Discovering deeper insights into malaria research

Malaria continues to drive urgent research worldwide, with new therapies and tools emerging to combat the parasite’s complex lifecycle and global burden.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue